Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Industry Roundup: Nature’s Way Licenses Chromax, Tauriga moves to supplements

This article was originally published in The Tan Sheet

Executive Summary

Nutrition 21, Nature’s Way settle patent case; Tauriga moves from food to supplements; Miami firm banned from weight loss market; national sales for Mary’s Nutritionals; and more news in brief.

You may also be interested in...



Pfizer Licenses Nutrition 21’s Chromax In Patent Claim Settlement

The settlement terms are confidential, but Pfizer “acknowledged the validity of Nutrition 21’s asserted patents” and the Centrum line “may continue to use chromium picolinate,” Nutrition 21 says. The firms agreed as attorneys prepared to begin questioning a pool of potential jurors for the trial.

QUOTED. 26 February 2020. Mark Leahey.

In an exclusive interview with Medtech Insight, Mark Leahey, president of the Medical Device Manufacturers Association (MDMA), said the previous four Medical Device User Fee negotiations with the US FDA have set a strong foundation for the industry and the next round of negotiations should focus on tweaking past deals that are already in place. See what MDMA's president, Mark Leahey, said about it here.

The Quality Lowdown: On Redeploying Inspectors, API Suppliers Thanks To Coronavirus

US investigators fan out to non-China inspection priorities and Secretary Azar talks supply management; warning letters hit record keeping, investigations and basic GMP compliance.

Topics

Related Companies

UsernamePublicRestriction

Register

PS107541

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel